Global Bioenergies Reports Full Year 2024 Earnings

Global Bioenergies (EPA:ALGBE) Full Year 2024 Results

Key Financial Results

• Revenue: €4.69m (up 44% from FY 2023).
• Net loss: €5.86m (loss narrowed by 32% from FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Global Bioenergies Earnings Insights

Looking ahead, revenue is expected to decline by 124% p.a. on average during the next 2 years, while revenues in the Chemicals industry in France are expected to grow by 5.1%.

Performance of the French Chemicals industry.

The company's shares are up 23% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 6 warning signs for Global Bioenergies (of which 3 are significant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.